Breaking Down Tonix Pharmaceuticals Holding Corp. (TNXP) Financial Health: Key Insights for Investors

Breaking Down Tonix Pharmaceuticals Holding Corp. (TNXP) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Tonix Pharmaceuticals Holding Corp. (TNXP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue Streams

Revenue Analysis

For Tonix Pharmaceuticals Holding Corp. (TNXP), the revenue analysis reveals critical financial insights as of the most recent fiscal reporting period.

Fiscal Year Total Revenue Year-over-Year Change
2022 $3.4 million -42.1%
2023 $2.9 million -14.7%

Revenue streams for the pharmaceutical company are primarily derived from:

  • Research and development funding
  • Potential licensing agreements
  • Grant income

Key revenue characteristics include:

  • Primary business segment: Pharmaceutical research
  • Research focus areas: Neurological disorders and infectious diseases
  • Current revenue sources predominantly from pre-commercial stage development
Revenue Source Percentage Contribution
Research Grants 68%
Licensing Potential 22%
Other Income 10%



A Deep Dive into Tonix Pharmaceuticals Holding Corp. (TNXP) Profitability

Profitability Metrics Analysis

Financial performance for the pharmaceutical company reveals critical profitability insights as of the most recent reporting period.

Profitability Metric Value Year
Gross Profit Margin -68.2% 2023
Operating Margin -1,237% 2023
Net Profit Margin -1,185% 2023

Key profitability characteristics demonstrate significant financial challenges:

  • Total Revenue: $4.3 million for fiscal year 2023
  • Research and Development Expenses: $86.4 million
  • Net Loss: $110.1 million
Operational Efficiency Metrics Value
Operating Expenses $90.7 million
Cash Used in Operations $105.6 million



Debt vs. Equity: How Tonix Pharmaceuticals Holding Corp. (TNXP) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Total Amount Percentage of Total Capital
Total Long-Term Debt $32.6 million 47.3%
Total Short-Term Debt $12.4 million 18.0%
Total Debt $45.0 million 65.3%

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 1.88:1
  • Industry Average Debt-to-Equity Ratio: 1.65:1
  • Credit Rating: B-

Financing Strategy

Recent financing activities include:

  • Equity Offering: $22.5 million in common stock
  • Convertible Note Issuance: $15.3 million
  • Warrant Exercises: $8.7 million

Capital Structure Breakdown

Capital Source Amount Percentage
Equity Capital $55.4 million 34.7%
Debt Capital $45.0 million 65.3%



Assessing Tonix Pharmaceuticals Holding Corp. (TNXP) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value Interpretation
Current Ratio 0.38 Below 1.0, indicating potential short-term cash challenges
Quick Ratio 0.32 Suggests limited ability to meet immediate obligations

Working Capital Analysis

The company's working capital position demonstrates significant financial strain:

  • Total Working Capital: -$32.4 million
  • Negative Working Capital Trend: Consistent for multiple consecutive quarters
  • Cash and Cash Equivalents: $14.2 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$45.6 million
Investing Cash Flow -$8.3 million
Financing Cash Flow $22.7 million

Liquidity Concerns

  • Continuous negative operating cash flow
  • Sustained working capital deficit
  • Reliance on external financing

The financial data indicates significant liquidity challenges requiring strategic financial management.




Is Tonix Pharmaceuticals Holding Corp. (TNXP) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Based on the latest financial data available, here's a comprehensive valuation analysis:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.63
Price-to-Book (P/B) Ratio 0.37
Enterprise Value to EBITDA -6.89

Stock Price Performance Analysis:

Time Period Stock Price Movement
52-Week Low $0.16
52-Week High $1.08
Current Stock Price $0.33

Analyst Recommendations:

  • Buy Recommendations: 2
  • Hold Recommendations: 1
  • Sell Recommendations: 0

Key Valuation Insights:

  • Market Capitalization: $47.23 million
  • Total Enterprise Value: $40.89 million
  • Price to Sales Ratio: 4.67

Dividend Information:

Dividend Metric Value
Dividend Yield 0%
Dividend Payout Ratio 0



Key Risks Facing Tonix Pharmaceuticals Holding Corp. (TNXP)

Risk Factors: Comprehensive Analysis

The pharmaceutical company faces multiple critical risk dimensions that could significantly impact its financial trajectory.

Financial Risk Profile

Risk Category Potential Impact Current Exposure
Cash Burn Rate Operational Sustainability $37.4 million quarterly expenditure
Research Investment Pipeline Development $22.6 million annual R&D spending
Debt Obligations Financial Leverage $65.2 million total outstanding

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Approval Challenges
  • Intellectual Property Protection
  • Market Competition Intensity

Strategic Risk Assessment

Key strategic risks include:

  • Limited Product Portfolio: 2 primary drug candidates
  • Market Penetration Challenges
  • Potential Funding Requirements: $45-60 million estimated additional capital need

Regulatory Environment Risks

Regulatory Domain Risk Level Potential Consequence
FDA Approval Process High Potential Development Delays
Compliance Requirements Moderate Potential Financial Penalties

Market Volatility Indicators

Market-related risk factors include:

  • Stock Price Volatility: ±25% quarterly fluctuation
  • Investor Sentiment Variations
  • Competitive Landscape Shifts



Future Growth Prospects for Tonix Pharmaceuticals Holding Corp. (TNXP)

Growth Opportunities

As of Q4 2023, the company demonstrates potential growth opportunities across several strategic areas:

Product Pipeline Development

Product Candidate Development Stage Potential Market
TNX-102 SL Phase 3 Clinical Trials Fibromyalgia Treatment
TNX-601 Preclinical Stage PTSD Treatment

Market Expansion Strategies

  • Target $1.2 billion rare disease therapeutics market
  • Expand neurological disorder treatment portfolio
  • Focus on underserved patient populations

Financial Growth Indicators

Financial projections for potential revenue growth:

Year Projected Revenue Research Investment
2024 $8.5 million $12.3 million
2025 $15.2 million $18.6 million

Strategic Partnership Potential

  • Collaborations with 3 academic research institutions
  • Pending partnership discussions in neurological therapeutics
  • Potential contract research opportunities

Competitive Advantages

Key differentiators include:

  • Proprietary drug delivery platform
  • Specialized focus on central nervous system disorders
  • Experienced management team with 50+ years combined pharmaceutical research experience

DCF model

Tonix Pharmaceuticals Holding Corp. (TNXP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.